ATRECA INC A Stock Price, News & Analysis

Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology firm, announced that CEO John A. Orwin will partake in a panel discussing novel oncology targets at Cowen’s 43rd Annual Health Care Conference, scheduled for March 7, 2023, from 9:10 to 10:20 AM EST.

The discussion will be accessible via a live webcast on the company's website, with an archived replay available for 30 days post-conference. Atreca specializes in developing innovative antibody-based immunotherapeutics through its unique discovery platform, aiming to advance its lead product candidate, ATRC-101, currently in a Phase 1b study for multiple solid tumor cancers.

Atreca, Inc. (NASDAQ: BCEL) and Xencor, Inc. have announced the initiation of a joint drug development program aimed at creating bispecific antibodies targeting solid tumors. This collaboration stems from their 2020 agreement, where Atreca provides novel tumor-binding antibodies. The first program focuses on APN-346958, an antibody targeting a novel RNA-binding protein, which shows potential across multiple tumor types. Atreca will lead the clinical development, with an investigational new drug (IND) submission planned by early 2025. Both companies will equally share costs and profits from the program.

Atreca, Inc. (NASDAQ: BCEL) has appointed Dr. Philippe Bishop as Chief Medical Officer, effective immediately. Dr. Bishop, an experienced medical oncologist, joins from Clover Biopharmaceuticals and has a strong background in cancer drug development. CEO John Orwin emphasized Dr. Bishop's expertise as crucial for advancing their lead product, ATRC-101, which is in a Phase 1b study for multiple solid tumors. New data from this study is expected to be released later this quarter. Dr. Bishop has been granted an option to purchase 350,000 shares of Atreca common stock.

Atreca, a clinical-stage biotechnology firm (NASDAQ: BCEL), reported its Q3 2022 financial results, showing a net loss of $23.1 million, or $0.60 per share. The company is actively enrolling patients in the Phase 1b trial for ATRC-101, with 67 participants enrolled so far. However, development of ADC candidate ATRC-301 is halted due to safety concerns. Additionally, progress continues for the malaria prevention candidate MAM01/ATRC-501, with an IND filing expected in early 2023. Atreca's cash and investments as of September 30, 2022, stood at $85.7 million.

Atreca, a clinical-stage biotechnology company trading under NASDAQ: BCEL, announces its participation in several upcoming conferences. The company will present at the Cowen 6th Annual IO Next Summit on November 11, 2022, followed by the Stifel Healthcare Conference on November 15-16, 2022, and the Evercore ISI HealthCONx Conference from November 29 to December 1, 2022. Live webcasts will be available on its website, with replays accessible for 30 days post-event. Atreca focuses on antibody-based immunotherapeutics, including its lead candidates ATRC-101 and ATRC-301.

Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced two poster presentations at the SITC 2022 Annual Meeting, scheduled for November 8-12 in Boston. The first presentation focuses on an interim update of the Phase 1b trial of ATRC-101, which is being evaluated as a monotherapy or in combination with Pembrolizumab for advanced solid tumors. The second presentation covers the preclinical development of a novel EphA2-targeted antibody. It’s noted that the ATRC-101 poster will not include new clinical data.

Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology company, will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, with a presentation scheduled for September 13 at 2:30 pm EDT. Additionally, Atreca will participate in the Baird Global Healthcare Conference on September 13-14, presenting at 2:00 pm EDT on September 14. Investors can access a live webcast of the H.C. Wainwright presentation on Atreca's website, with an archived replay available for 30 days.

Atreca, Inc. (NASDAQ: BCEL) reported its second quarter financial results as of June 30, 2022, demonstrating a net loss of $27.9 million, equating to a loss of $0.72 per share. As of the reporting date, the company had cash and equivalents totaling $101.7 million. Atreca is prioritizing the development of its clinical candidates, ATRC-101 and ATRC-301, with updates expected in the second half of 2022. Key recent developments include the appointment of Dr. Stephen Gould as Chief Scientific Officer and ongoing enrollment in the Phase 1b clinical trial for ATRC-101.

Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced its participation in two upcoming investor conferences. The company will present at the Wedbush PacGrow 2022 Healthcare Conference on August 9, and at the Canaccord Genuity 42nd Annual Growth Conference on August 10. A live audio webcast of the Canaccord presentation will be available on Atreca's website, with an archived replay following the event. Atreca focuses on developing novel antibody-based immunotherapeutics, including its lead candidate ATRC-101, currently in a Phase 1b study for multiple solid tumor cancers.